Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in IPF therapeutics.

• There will be more than 0.49 million diagnosed prevalent cases of IPF in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for IPF.
• Currently, there are two leading marketed drugs for the treatment of IPF, with Roche and Boehringer Ingelheim being key players in the disease space.
• R&D activity in IPF is steady, with one product in pre-registration stage and three products in Phase III development.
• Commercial sponsors dominate clinical trial development in IPF, with the US emerging as the key country for conducting trials in this disease space.
• Globally, deals involving partnerships were the most common type of deals involving companies developing
• There will be more than 0.49 million diagnosed prevalent cases of IPF in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for IPF.
• Currently, there are two leading marketed drugs for the treatment of IPF, with Roche and Boehringer Ingelheim being key players in the disease space.
• R&D activity in IPF is steady, with one product in pre-registration stage and three products in Phase III development.
• Commercial sponsors dominate clinical trial development in IPF, with the US emerging as the key country for conducting trials in this disease space.
• Globally, deals involving partnerships were the most common type of deals involving companies developing IPF assets.

Scope

GlobalData's IPF: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the IPF market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.